Richard Knight, MD
Surgery · Houston, TXNPI 1730111345
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $80,391 of the $102,688 with a category attached, or 78.3%. 7 manufacturers reported payments, led by Takeda Pharmaceuticals U.S.A., Inc. at 42.8% of the total. Reporting peaked in 2023 at $35,502 and has fallen 99.7% since, to $90 in 2025. Among surgery clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 69 payments — averaging $1488.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$44K
- Sanofi-aventis U.S. LLC$35K
- One Lambda, Inc.$13K
- Sanofi$11K
- Veloxis Pharmaceuticals, Inc.$156
- Kamada Ltd.$76
- plus $24 from 1 others
Across 4 payments — averaging $11,017 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$40K
- Novartis$4K
What the payments were for
- Consulting fees$11,80011%
- Speaking & faculty fees$80,39178%
- Travel & lodging$7,9508%
- Food & beverage$2,5472%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 29 | $43,987 |
| Sanofi-aventis U.S. LLC | 19 | $34,568 |
| One Lambda, Inc. | 5 | $13,368 |
| Sanofi | 11 | $10,510 |
| Veloxis Pharmaceuticals, Inc. | 3 | $156 |
| Kamada Ltd. | 1 | $76 |
| Smith+Nephew | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- THYMOGLOBULIN$44,861
- LIVTENCITY$43,711
How this compares
$102,688 in reported general payments places this provider in the 95th percentile of 1,830 surgery providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 16 | $17,288 |
| LokelmaSodium Zirconium Cyclosilicate | 11 | $15,198 |
| Sirolimus | 17 | $12,975 |
| EliquisApixaban | 18 | $12,557 |
| Atovaquone | 19 | $9,931 |
| Valganciclovir Hcl | 36 | $6,874 |
| Mycophenolic AcidMycophenolate Sodium | 20 | $6,694 |
| Tacrolimus | 38 | $6,654 |
| Mycophenolate Mofetil | 15 | $1,756 |
| Fludrocortisone Acetate | 17 | $990 |
| Nifedipine ErNifedipine | 25 | $709 |
| Prednisone | 118 | $707 |
| Famotidine | 39 | $663 |
| Atorvastatin Calcium | 81 | $651 |
| Gabapentin | 27 | $543 |
Paid to pharmacies, not to this prescriber.
Other surgery in Houston
- James SuliburkHouston$161K
- Funda MericHouston$141K
- Jonathan StahlHouston$105K
- Tanyaradzwa KajeseHouston$92K
- Michael HarkinsTomball$2.7M
- Douglas StoddardAustin$1.4M
- Steven FassAustin$989K
- Vineet ChoudhryAustin$851K
- Andy HawthorneRound Rock$843K
- Nancy MarquezAustin$700K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.